Patients with normal ovarian response undergoing GnRH antagonist protocol
Conditions
Interventions
Depot GnRH agonist protocol control group:Standard depot GnRH agonist protocol
GnRH antagonist protocol control group:Standard GnRH antagonist protocol
GnRH antagonist protocol study group:Standard GnRH antagonist protocol with growth hormone treatment
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1. Women of reproductive age: 20-35 to be specific; 2. Women with regular menstural cycle: 25-35 days to be specific; 3. Women with normal body mass index (BMI) according to Asia criteria: 18.5-25 kg/m2; 4. Women with normal ovarian reserve: follicle-stimulating hormone < 10 IU/mL, antral follicle count 7-15 and/or Anti-Mullerian hormone 1.1-4.0 ng/mL; 5. Patients undergoing their first IVF-ET or ICSI-ET cycles.
Exclusion criteria
Exclusion criteria: 1. AFC 15, and AMH 4.0ng/ml; 2. PCOS patients according to Rotterdam standard; 3. Abnormalities of ovary or adnex: ovarian cyst, untreated severe hydrosalpinx, endometriosis, etc; 4. Abnormalities of uterus: adenomyosis, submucous myoma or intramural myoma affecting the uterine cavity, genital malformation, endometrial polyp, uterine cavity adhesion, thin endometrium, etc; 5. Patients with PGT indications, including: paternal or maternal chromosome abnormality, RIF, RSA, monogenetic disease, etc; 6. Patients undergoing ICSI cycle for the following reason: azoospermia or severe oligozoospermia (WHO 5th edition standard), PESA, TESA; 7. Systematic disease: thyroid disease, diabetes, adrenal gland abnormality, chronic disease without control/treatment, disease not suitable for pregnancy; 8. Patients with growth hormone contradictions, including: diabetes, severe systematic infections, cancer with active state, Intracranial injury, pregnancy, etc; 9. Recently treated with other medicines, including: OC, estrogen, CoQ10, Metformin, etc; 10. Enrolled in other clinical trials simultaneously or considered not appropriate for this trial according to the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ongoing pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| total Gn dose;endometrium thickness on trigger day;Number of oocytes retrieved;Number of high quality embryos;clinical pregnancy rate;miscarriage rate; | — |
Countries
China
Contacts
Public ContactJing Yue
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed